The FDA has expanded the approval of Furoscix to include treatment of congestion due to fluid overload in adult patients with ...

Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024SOUTH SAN ...

Hopital National Ignace Deen, Conakry, Guinea. 3 Hopital de L’amitié Sino-Guineenne, Conakry, Guinea. Despite current ...

However, the association between Lp(a) and adverse outcomes in patients with ischemic heart failure (IHF) remains unclear ... and body mass index (BMI), New York Heart Association (NYHA) class, ...

With the heart failure (HF) patient population rapidly expanding, the timing is right for Bayer’s Kerendia (finerenone). The nonsteroidal mineralocorticoid receptor antagonist (MRA) was approved ...

The study’s completion data was June 14, 2024. 7 Secondary outcomes of interest were total heart failure events, NYHA disease class improvement to 12 months, all-cause mortality, renal composite ...

There are limited treatment options for the large population of patients with heart failure (HF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF).  In the FINEARTS-HF trial, finerenone ...

A medication that is currently used for chronic kidney disease in patients with type 2 diabetes has been found to reduce the risk of worsening heart failure and cardiovascular death in certain ...

Patients with heart failure with reduced ejection fraction ... There were no differences in the NYHA [New York Heart Association] class, which is a broad way of understanding how short of breath ...

Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and ...